TherOx pushes for FDA approval with $30m:
This article was originally published in Clinica
Executive Summary
TherOx, an Irvine, California-based company that is developing an oxygen therapy to help heart attack patients, has secured $30m to help take its product through to FDA approval. The financing was led by DAG Ventures. Some of the funds will also be used to initiate US commercialisation of the device, pending approval. TherOx's SuperSaturated Oxygen (SSO2) therapy is designed as an adjunct to balloon angioplasty and stent procedures. It helps to salvage heart muscle by delivery highly oxygenated arterial blood directly to tissue damaged by myocardial infarction.